^
Association details:
Biomarker:No biomarker
Cancer:Acute Myelogenous Leukemia
Drug:decitabine (DNMT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
09/20/2012
Excerpt:
Dacogen is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
AML:…Therapy for relapsed/refractory disease…less aggressive therapy…hypomethylating agents (azacitidine or decitabine)